ArticleJACC. Advances2026
Prognostic Utility of the HFpEF-ABA Score for HFpEF Patients: Insights From the TOPCAT Trial.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00094302 (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe HFpEF-ABA score, incorporating age, body mass index (BMI), and atrial fibrillation (AF), has demonstrated utility in patients with heart failure with preserved ejection fraction (HFpEF).
objectivesThis study evaluated the prognostic performance of the HFpEF-ABA score within the Americas and Russia/Georgia cohorts of the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial, examining its association with clinical outcomes across these distinct regions.
methodsCox proportional hazards and competing risk regression analyses assessed associations between HFpEF-ABA probabilities and clinical outcomes.
resultsAmong the Americas cohort (n = 1,726), 72.7% exhibited an HFpEF-ABA probability ≥75%. Elevated HFpEF-ABA probabilities were modestly associated with an increased risk of HF hospitalization HR per 10% increase: 1.07; 95% CI: 1.00-1.14) and any hospitalization (HR per 10% increase: 1.04; 95% CI: 1.00-1.08), without significant associations with mortality or major cardiovascular events. In the Russia/Georgia cohort (n = 1,674), 39.8% had probability ≥75%. Higher HFpEF-ABA probabilities were significantly associated with increased risks of all-cause mortality (HR: 1.67; 95% CI: 1.16-2.41), heart failure hospitalization (HR: 1.98; 95% CI: 1.04-3.78), any hospitalization (HR: 1.75; 95% CI: 1.43-2.14,) and stroke (HR: 2.81; 95% CI: 1.44-5.5). A linear trend of escalating adverse outcome risks corresponded with increasing HFpEF-ABA probabilities in the Russia/Georgia cohort, excluding stroke.
conclusionsOur study demonstrates substantial regional heterogeneity in the prognostic utility of the HFpEF-ABA score among patients with HFpEF enrolled in the TOPCAT trial. The score exhibited strong associations with adverse outcomes in the Russia/Georgia cohort, whereas its prognostic discrimination was attenuated in the Americas cohort. (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function [TOPCAT]; NCT00094302).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.